Voyageur Pharmaceuticals completes commercial delivery

Executive Summary

• Voyageur Pharmaceuticals made its first commercial shipment of Health Canada‑approved barium contrast products to a leading Canadian radiology provider.
• The sale supports the Frances Creek barium sulphate project by providing data for FDA filings and financing the final feasibility study.
• Company highlights low‑cost production ($620‑$650/tonne) and a 121,000‑tonne resource with an NPV of $344 million, positioning Voyageur for scalable growth in North America.

Key Details

• First commercial delivery of the full suite of barium contrast agents (SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD) to a Canadian radiology provider that placed a purchase order in June 2025.
• Delivery meets the company’s milestone to ship product by end‑August 2025.
• President & CEO Brent Willis states the sale “will be a critical component of our FDA filings … and is expected to provide the economics to complete our final feasibility study” for the Frances Creek project.
• Production cost estimate for barium sulphate from Frances Creek: $620–$650 per tonne, versus imported API costs of ~$10,000 per tonne.
• Frances Creek resource: 121,000 tonnes (indicated & inferred) with a net present value of $344 million.
• Strategic advantages cited: low‑cost supply, long‑term availability, North American supply‑chain independence, and plans for carbon‑neutral operations using advanced capture technology.
• Company is expanding distribution across Canada while leveraging the vertical integration model to improve margins and quality control.
• Contact for purchasing inquiries: Ethan Mohan ([email protected]).

Notable Quotes

“This sale has many important aspects for the development of the Frances Creek project and anticipated global expansion… The data accumulated from the use of our products will be a critical component of our FDA filings to enter the U.S. market…” – Brent Willis, President & CEO